Coronary artery bypass graft surgery Circulatory System Coronary artery bypass graft surgery
Conditions
Interventions
We randomized patients to receive four (two intraoperative and two postoperative) doses of intravenous N-acetylcysteine 600 mg or placebo over a 24-hour period.
Sponsors
The Physician Services Incorporated Foundation (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Elective or urgent coronary artery bypass graft surgery patients with at least one of: pre-esisting renal dysfunction, age greater than or equal to 70, diabetes mellitus, impaired left ventricular function or undergoing concomitant valve or redo surgery.
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the proportion of patients developing postoperative renal dysfunction, defined by an increase in serum creatinine level greater than 0.5 mg/dL (44 micromol/L) or a 25% increase from baseline within the first 5 postoperative days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes included postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay. | — |
Countries
Canada
Outcome results
None listed